Massachusetts General Hospital

Juniper Pharmaceuticals formation scientific advisory board

Friday, April 24, 2015

Juniper Pharmaceuticals, a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health, has created a scientific advisory board (SAB) comprised of international physicians and scientists whose mission will be to provide scientific and clinical advice on the identification and advancement of product candidates for Juniper’s women’s health portfolio.

[Read More]

ALS Association, Harvard, Massachusetts General collaborate with GSK

Friday, April 17, 2015

The ALS AssociationHarvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In parallel testing, brain cells will be made from each patient’s stem cells to see if they can predict which patients might respond to the medicine.

[Read More]

NIH forms team to chart course for Precision Medicine Initiative research network

Wednesday, April 1, 2015

A newly created team of experts in precision medicine and large clinical research studies will seek public input from the large and diverse stakeholder community interested in the development of the President’s Precision Medicine Initiative and articulate the vision for building the national participant group for the Initiative. They will help define what can be learned from a study of this scale and scope, what issues will need to be addressed and considered as part of the study design and what success would look like five and 10 years out.

[Read More]

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

[Read More]

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Monday, March 23, 2015

Apple has taken a key step this month toward helping to improve patient recruitment for medical studies with ResearchKit, a new iPhone-based medical software platform researchers can use to de­sign and administer app-based observational studies. ResearchKit will help both doctors and researchers gather patient data frequently and more accurately track disease signs using sen­sors that are on the iPhone.

[Read More]

The Medicines Company acquires Annovation Biopharma

Thursday, February 5, 2015

The Medicines Company has completed its acquisition of all of the outstanding equity of Annovation Biopharma, a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in phase I clinical studies has demonstrated potent and rapidly reversible anesthetic effects.

[Read More]

Infraredx, Massachusetts General Hospital collaborate on cardiovascular imaging devices

Wednesday, December 17, 2014

Infraredx, a Burlington, Mass.-based cardiovascular imaging company, is collaborating with Massachusetts General Hospital (MGH) and coronary imaging researcher Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.

[Read More]